Share Name Share Symbol Market Type Share ISIN Share Description
Byotrol Plc LSE:BYOT London Ordinary Share GB00B0999995 ORDS 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 3.40p 3.20p 3.60p 3.40p 3.40p 3.40p 235,168 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 3.1 -0.2 -0.1 - 13.70

Byotrol Share Discussion Threads

Showing 6701 to 6725 of 6725 messages
Chat Pages: 269  268  267  266  265  264  263  262  261  260  259  258  Older
DateSubjectAuthorDiscuss
27/8/2018
18:10
If Target are giving away Byotrol as samples then I very much doubt it's costing Target anything.. If they can break into the US market then great but the US is a very tough market to crack... Especially as Trump's message is America First, Buy America, Hire American.. Let's see if they announce an update on the trial and if it's extended to all Target stores...
sikhthetech
27/8/2018
10:21
It makes no sense as a consumer product. Joe public can't see bacteria in their homes so can't tell if it is working. If they buy it, how do they judge whether it is any good. " we didn't get food poisoning this month so it must be the byotrol" ?If it's anything like the Tesco product, in my experience, it may kill bugs but it isn't a great cleaner.Add to that the current evidence that the reduction in bacteria in homes may be causing everything from asthma to leukaemia and it really has no place as a domestic product.It makes sense as a cleaner in clinical settings and in food preparation businesses but it has no traction there.Poor management, poor marketing and still only exists to pay inflated salaries to the few.
brownson
24/8/2018
12:48
Doesn't matter about the discount it matters about units sold in the shop and at what price and Byotrol24 is a premium product with a premium price and is selling. Also you need to find out about repeat customers lots of people will try a product once when it's new a container of Byotrol24 is going to last a good few weeks at least so you won't know if it's a success or not for a couple months down the line when people start buying it a second or third time. So that could be why the trial is being extended as well.
football
24/8/2018
12:40
slice/cumnor, yes, agree Target probably want more data, especially if the products are selling but not flying off the shelves... If they were flying off the shelves then i think they would have rolled out the product across all Target stores and not just 10% of them... During the trial, are the products being offered at a generous discount or SOR?
sikhthetech
24/8/2018
12:30
A couple of decent confidence-confirming buys today from directors after yesterday's results.
milesy
24/8/2018
12:29
Look at that just like London buses as they come along in pairs directors buying again
football
24/8/2018
12:25
Am I right in thinking even though we are paying £4.5 million it's really only going to be about £4 million as we allocated £500,000 this year to set up a sales team which we have bought purchasing Medimark Scientific, so have save them costs and have a proven up and running sales arm of the company now to push the joint venture along at full speed. Also this deal must of took ages to set up and with a very small management team must of probably took a lot of their time so maybe not focused on the target stuff at all but with the new sales team they may be able to push the product a bit more now.
football
24/8/2018
08:33
https://www.insidermedia.com/insider/northwest/byotrol-acquires-infection-control-specialist-for-4.5m
football
24/8/2018
00:04
Byotrol - FY 2018 and transformative acquisition Full-year results were ahead of expectations, with an adjusted EBITDA of £44k versus an expected £350k loss, but helped by the accounting treatment for the sale of Actizone patents to Solvay. Byotrol also announced the acquisition of Medimark Scientific, which sells infection control products for the Animal Health and Human Healthcare markets. The £4.5m consideration (including a two-year £1.8m earnout), implies an EV/EBITDA of 7.1x. The combination not only creates critical mass, but it brings .... https://www.research-tree.com/companies/uk/specialty-chemical/byotrol/research/finncap/byotrol-fy-2018-and-transformative-acquisition/8_CN35_3_1
football
24/8/2018
00:02
Byotrol makes good progress and a £4.5m acquisition Hygiene specialist Byotrol enjoyed “a year of good progress”, it reported in its latest annual results to March 31. The Daresbury-based company also announced the £4.5m acquisition of Kent-based Medimark Scientific. Byotrol managed a small increase in revenues, from £3.127m to £3.140m, and an almost doubling of pre-tax losses, from £126,427 to £244,939. However, chief executive David Traynor said it had managed to record its second consecutive profit at EBITDA level, after including R&D tax credits. EBITDA was “significantly ahead of expectations,” the company said. The firm’s financial strength was improved by a £4.6m equity capital raising in September, 2017, and net cash at the year end stood at £3.9m, compared with £951,000 the previous year. Today’s statement said Byotrol now has “more than sufficient resources” to pursue its growth strategy. In May this year the AIM-listed anti-microbial technology firm revealed it had received approval for its germ-killing product in the US, known as Byotrol24, and received its first orders to retail on online giant Amazon. It is one of three strategic initiatives being followed by the company Its Actizone initiative has been restructured, generating immediate cash from an IP sale, while retaining a substantial future upside for less resource input. Byotrol24 is now under trial, which has been extended beyond the initial 10-week expected period. And the firm’s alcohol-free hand sanitisers are now being sold into NHS and adjacent markets. There is substantial customer interest but resource requirements are higher and sales are slower than expected, the firm admitted. The consumer and petcare segments are performing to plan, with significant growth opportunities, although the professional segment is behind plan, with new propositions now being developed and new alliance partners being sought. Sevenoaks-based Medimark Scientific provides biocide-based infection control products into the animal and human healthcare markets. It employs 14 staff and in the year to March 31, reported adjusted EBITDA of £380,000 on revenues of £2.7m. There is an existing and long-standing relationship already in place between the two companies – Byotrol is currently a white label supplier of hand sanitisers to Medimark, which it sells under its Esense brand. Commenting on the results and prospects, Byotrol chief executive David Traynor said: “This was another year of good progress, with further-improved operations and finances and our second ever profit at EBITDA level after including R&D tax credits. “We continue with our excellent-science, technology-based strategy and are very confident in growth at home and overseas as the biocide regulatory changes bite.” https://www.thebusinessdesk.com/northwest/news/2027215-byotrol-makes-good-progress-4.5m-acquisition
football
23/8/2018
23:17
Agree slice, it would have been off the shelf in weeks (irrespective of agreements) had it not been generating some interest. A positive no matter the eventual outcome.
cumnor
23/8/2018
21:51
Businesses such as target are pretty ruthless unlikely to give a second chance/ favour to a small co like Byotrol so inclined to view this as positive and suspect they want more sales data.
slicethepie
23/8/2018
20:36
gems everywhere but still can't get rid of the one above
football
23/8/2018
19:47
slicethepie, If a trial is extended, it could be because the sales figures haven't been convincing... How much of a discount did BYOT give to Target to trial it's cleaner?.
sikhthetech
23/8/2018
17:18
Footie - looks like it's complementary IP that Byotrol want to own and leverage in-house.
milesy
23/8/2018
14:55
1gw Speedos or Bermuda shorts? Can't wear Speedos anymore because I look like the bloke at the Southern Comfort advertThe new acquisition is it because of their products or is it maybe because if target take up our product we need to upscale manufacturing
football
23/8/2018
13:29
Byotrol24 selling for $4.29 in Target for just under 1 ltr: hTTps://www.target.com/s?searchTerm=byotrol Seems the company have been soliciting reviews (generally positive) with free samples. Like the shape of today's results and acquistion.
milesy
23/8/2018
13:10
Nice surprise on my return from the beach! Good to see them get the results out today in the end and I like the fact that the acquisition shares are priced above 4p. Also I agree it sounds like good news that the Target trial is being extended - although I suppose it could mean the results are borderline and they need more time to decide whether it is going to be viable.
1gw
23/8/2018
12:59
Sorry. Out again. Potentially paying 4.5 million for a company without equity and a profit of 218k (2018) (17k loss in 2017 and accumulated losses till 2017 of 227k) is a bit too generous imo. BOL holders.
greedfear
23/8/2018
12:44
Let's hope for a bit more positive press a long with a bit more institution coverage along with PR from the investor relations team Seem to be on the boil with Facebook but Twitter looks dormant nice interactive poll about germs on the Facebook page from Monday https://twitter.com/byotrol https://tinyurl.com/y9dsbmcc
football
23/8/2018
12:41
Presumably must be going pretty well .....Now under trial under the brand 'Byotrol24' in US mass merchandiser Target. Trial now extended beyond the initial 10 week expected period.
slicethepie
23/8/2018
12:33
Just need a bit of news from the USA about the target trials and hopefully good news so we can start supplying all their stores
football
23/8/2018
12:20
Lets see .. but it sounds good. hTtp://www.medi-mark.co.uk/
maxk
23/8/2018
11:54
Looks a good deal at first glance Consideration of up to £4.5m is payable in respect of the Acquisition, which includes £0.4m of debt that Byotrol is assuming. Initial consideration of £2.3m is payable on completion, being £1.15m in cash and £1.15m from 28,048,780 new ordinary shares ("Ordinary Shares") being issued at 4.1p per share. An additional £1.8m of consideration is payable subject to achieving EBITDA targets in FYE 31 March 2019 and FYE March 2020. The deferred consideration is also to be paid half in cash and half in new ordinary shares.
tanneg
23/8/2018
11:37
Well looks like results are out and looks like they are expecting growth and have the money to do so rather than just surviving along with an acquisition to help along with their expansion and growth. Looks like a lot of works been going on in the background setting it all up so that's out they can carry out the business plan
football
Chat Pages: 269  268  267  266  265  264  263  262  261  260  259  258  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20180919 18:49:05